TAK-981 is a first-in-class inhibitor of the SUMOylation enzymatic cascade being developed for the treatment of multiple myeloma.
| SparkCures ID | 409 |
|---|---|
| Developed By | Takeda Oncology |
| Generic Name | TAK-981 |
| Treatment Classifications |
|
There are no resources, links or videos to display for this treatment.